ICON Signs Collaboration Agreement with the Taiwan National Centre of Excellence for Clinical Trials and Research

Dublin, Ireland, 7 August, 2013 – ICON plc, (NASDAQ: ICLR) a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, and the National Clinical Trials and Research Centre (NCTRC) at the National Taiwan University Hospital, today announced a collaboration agreement to enhance the set-up and management of clinical studies in Taiwan.

Under the terms of the agreement NCTRC and ICON will work together on study start-up, site feasibility, key site and investigator selection and patient recruitment. Both organisations will also work together on further enhancing the already high standards of clinical research in Taiwan.

"We are very pleased to be collaborating with the NCTRC who are at the forefront of clinical research in Taiwan," commented Wei Ming Goh, ICON's Vice President, Asia-Pacific. "Our customers are increasingly looking to include Taiwan in their clinical programmes and are expecting fast timelines for study start-up and patient recruitment. By combining the proven expertise of ICON and NCTRC in the region, we can further accelerate study timelines which will benefit our customers and also enhance the Taiwanese clinical trials industry."

"The aim of this partnership is to accelerate new drug development and new treatments for diseases and we hope to achieve this by leveraging our respective strengths," commented Professor Chan Wing Kai, Director of NCTRC. "We are happy to be collaborating with ICON, a leading clinical research organisation that has proven experience in both global and local clinical development programmes."

The National Centre of Excellence for Clinical Trial and Research (NCTRC) at National Taiwan University Hospital is a center of excellence for clinical studies in Asia Pacific and the preferred partner of major international pharmaceutical companies. We take leadership in a number of international clinical trials as study chairman or steering committee members.

About ICON plc
ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The company specialises in the strategic development, management and analysis of programs that support clinical development - from compound selection to Phase I-IV clinical studies. ICON currently has 10,170 employees, operating from 78 locations in 37 countries. www.iconplc.com

Suggested Articles

Genesis Drug Discovery & Development has bought up New England Discovery Partners as it looks to boost its synthetic and medicinal chemistry.

Sanofi plans to incorporate its real-world data platform with Aetion’s analytics system to better develop studies for regulatory decision-making.

Major CRO player Pharmaceutical Product Development is set to go back on the public markets after announcing its IPO plans.